With Zyrtec In Front, Consumer Segment Leads J&J’s Performance
This article was originally published in The Tan Sheet
Executive Summary
Sales of Zyrtec helped Johnson & Johnson's consumer business offset the impact of generics on its prescription drug division in its latest earnings period